Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26097473 | 0.79 | TGFBR1 (0.48) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL18006555 | 0.79 | MAPT (0.65) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL925682 | 0.78 | CCR1 (0.52) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL924763 | 0.77 | TGFBR1 (0.53) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL924644 | 0.77 | CDK2 (0.50) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL14825063 | 0.76 | NPC1 (1.00) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL3661251 | 0.76 | CDK4 (0.57) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL22684842 | 0.76 | CDK4 (0.76) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL11796387 | 0.76 | TGFBR1 (0.56) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18469879 | 0.76 | NPC1 (0.45) | MAPTALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | claimed |
| EP-1841763-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2007-10-10 | — | — | EP | claimed |
| WO-2006051270-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | claimed |
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-2016075-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| WO-2007129044-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| EP-1841763-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006051270-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
| US-4735957-A | ANTIULCER AGENTS, CARDIOTONIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
| US-4649146-A | ANTIULCER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0117082-A2 | Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | MTOR, RPTOR, JAK2 | MAPT 2307/4885ALDH1A1 1838/4885NPC1 1535/4885 |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | MAPT 1887/4885ALDH1A1 2310/4885NPC1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.